How to handle adsorption of cerebrospinal fluid amyloid β (1–42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Aβ42/Aβ40 ratio

Alzheimer's and Dementia

Volumn 13, Issue 8, 2017, Pages 885-892

  Willemse, Eline ^a,b   van Uffelen, Kees ^a   Brix, Britta ^c   Engelborghs, Sebastiaan ^d,e   Vanderstichele, Hugo ^f   Teunissen, Charlotte ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Institute of Experimental Immunology   (Germany)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e Hospital Network Antwerp   (Belgium)

^f ADX NEUROSCIENCES   (Belgium)

Author keywords

Adsorption; Alzheimer's disease; Amyloid (1 40); Amyloid (1 42); Biobanking; Biomarkers; Cerebrospinal fluid; Preanalytical variation; Ratio A 42 A 40

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; POLYPROPYLENE; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ADSORPTION; ARTICLE; CEREBROSPINAL FLUID; CLINICAL LABORATORY; CLINICAL PRACTICE; HUMAN; INCUBATION TIME; LABORATORY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; CHEMISTRY; DEVICES; ENZYME LINKED IMMUNOSORBENT ASSAY; PRE-ANALYTICAL PHASE; QUESTIONNAIRE; STATISTICAL MODEL; TIME FACTOR;

ADSORPTION; AMYLOID BETA-PEPTIDES; BIOMARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LINEAR MODELS; PEPTIDE FRAGMENTS; PRE-ANALYTICAL PHASE; SURVEYS AND QUESTIONNAIRES; TIME FACTORS;

EID: 85015790447     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2017.01.010     Document Type: Article

References (38)

1. Scheltens, P., Blennow, K., Breteler, M.M.B., de Strooper, B., Frisoni, G.B., Salloway, S., et al. Alzheimer's disease. Lancet 388 (2016), 505–517.
2. Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., et al. Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease. Arch Neurol, 56, 1999, 673.
3. Vanderstichele, H., Blennow, K., D'Heuvaert, N., Buyse, M.-A., Wallin, A., Andreasen, N., et al. Development of a Specific Diagnostic Test for Measurement of p-amyloid (1–42) lPA4{1-42)] in CSF. 1998, Plenum Press, New York.
4. Bjerke, M., Portelius, E., Minthon, L., Wallin, A., Anckarsäter, H., Anckarsäter, R., et al. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int J Alzheimers Dis 2010 (2010), 1–12.
5. Teunissen, C.E., Petzold, A., Bennett, J.L., Berven, F.S., Brundin, L., Comabella, M., et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73 (2009), 1914–1922.
6. Teunissen, C.E., Verwey, N.A., Kester, M.I., van Uffelen, K., Blankenstein, M.A., Standardization of assay procedures for analysis of the CSF biomarkers amyloid β((1-42)), tau, and phosphorylated tau in Alzheimer's disease: report of an international workshop. Int J Alzheimers Dis 2010 (2010), 1–6.
7. Perret-Liaudet, A., Pelpel, M., Tholance, Y., Dumont, B., Vanderstichele, H., Zorzi, W., et al. Risk of Alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes. J Alzheimers Dis 31 (2012), 13–20.
8. Kofanova, O.A., Mommaerts, K., Betsou, F., Tube polypropylene: a neglected critical parameter for protein adsorption during biospecimen storage. Biopreserv Biobank 13 (2015), 296–298.
9. Pica-Mendez, A.M., Tanen, M., Dallob, A., Tanaka, W., Laterza, O.F., Nonspecific binding of Aβ42 to polypropylene tubes and the effect of Tween-20. Clin Chim Acta, 411, 2010, 1833.
10. Lehmann, S., Schraen, S., Quadrio, I., Paquet, C., Bombois, S., Delaby, C., et al. Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. Alzheimers Dement 10:5 Suppl (2014), S390–S394.
11. Leitão, M.J., Baldeiras, I., Herukka, S.K., Pikkarainen, M., Leinonen, V., Simonsen, A.H., et al. Chasing the effects of pre-analytical confounders—a multicenter study on CSF-AD biomarkers. Front Neurol, 6, 2015, 153.
12. Vanderstichele, H.M., Janelidze, S., Demeyer, L., Coart, E., Stoops, E., Herbst, V., et al. Optimized standard operating procedures for the analysis of cerebrospinal fluid Aβ42 and the ratios of Aβ isoforms using low protein binding tubes. J Alzheimers Dis 53 (2016), 1121–1132.
13. Toombs, J., Paterson, R.W., Lunn, M.P., Nicholas, J.M., Fox, N.C., Chapman, M.D., et al. Identification of an important potential confound in CSF AD studies: aliquot volume. Clin Chem Lab Med 51 (2013), 2311–2317.
14. Toombs, J., Paterson, R.W., Schott, J.M., Zetterberg, H., Amyloid-beta 42 adsorption following serial tube transfer. Alzheimers Res Ther, 6, 2014, 5.
15. del Campo, M., Mollenhauer, B., Bertolotto, A., Engelborghs, S., Hampel, H., Simonsen, A.H., et al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med 6 (2012), 419–430.
16. Perret-Liaudet, A., Pelpel, M., Tholance, Y., Dumont, B., Vanderstichele, H., Zorzi, W., et al. Cerebrospinal fluid collection tubes: a critical issue for Alzheimer disease diagnosis. Clin Chem 795 (2012), 787–789.
17. Sutphen, C.L., Jasielec, M.S., Shah, A.R., Macy, E.M., Xiong, C., Vlassenko, A.G., et al. Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol 72 (2015), 1029–1042.
18. Lewczuk, P., Beck, G., Esselmann, H., Bruckmoser, R., Zimmermann, R., Fiszer, M., et al. Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid β peptides. Clin Chem 52 (2006), 332–334.
19. Lachno, D.R., Evert, B.A., Maloney, K., Willis, B.A., Talbot, J.A., Vandijck, M., et al. Validation and clinical utility of ELISA methods for quantification of amyloid- β of peptides in cerebrospinal fluid specimens from Alzheimer's disease studies. J Alzheimers Dis 45 (2015), 527–542.
20. Cullen, V.C., Fredenburg, R.A., Evans, C., Conliffe, P.R., Solomon, M.E., Development and advanced validation of an optimized method for the quantitation of Aβ42 in human cerebrospinal fluid. AAPS J 14 (2012), 510–518.
21. Poncin-Epaillard, F., Vrlinic, T., Debarnot, D., Mozetic, M., Coudreuse, A., Legeay, G., et al. Surface treatment of polymeric materials controlling the adhesion of biomolecules. J Funct Biomater 3 (2012), 528–543.
22. Wiltfang, J., Esselmann, H., Bibl, M., Hüll, M., Hampel, H., Kessler, H., et al. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-tau in patients with low- and high-CSF A beta 40 load. J Neurochem 101 (2007), 1053–1059.
23. Hansson, O., Zetterberg, H., Buchhave, P., Andreasson, U., Londos, E., Minthon, L., et al. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 23 (2007), 316–320.
24. Zimmermann, R., Lelental, N., Ganslandt, O., Maler, J.M., Kornhuber, J., Lewczuk, P., Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics. J Alzheimers Dis 25 (2011), 739–745.
25. Slemmon, J.R., Shapiro, A., Mercken, M., Streffer, J., Romano, G., Andreasen, N., et al. Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with Aβ42 and influence of disease on the total-Aβ42/Aβ40 ratio. J Neurochem 135 (2015), 1049–1058.
26. Lewczuk, P., Lelental, N., Spitzer, P., Maler, J.M., Kornhuber, J., Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays. J Alzheimers Dis 43 (2014), 183–191.
27. Dorey, A., Perret-Liaudet, A., Tholance, Y., Fourier, A., Quadrio, I., Cerebrospinal fluid Aβ40 improves the interpretation of Aβ42 concentration for diagnosing Alzheimer's disease. Front Neurol 6 (2015), 1–7.
28. Dumurgier, J., Schraen, S., Gabelle, A., Vercruysse, O., Bombois, S., Laplanche, J.L., et al. Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimers Res Ther 7 (2015), 1–9.
29. Sauvée, M., DidierLaurent, G., Latarche, C., Escanyé, M.C., Olivier, J.L., Malaplate-Armand, C., Additional use of Aβ42/Aβ40 ratio with cerebrospinal fluid biomarkers P-tau and Aβ42 increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice. J Alzheimers Dis 41 (2014), 377–386.
30. Bjerke, M., Andreasson, U., Kuhlmann, J., Portelius, E., Pannee, J., Lewczuk, P., et al. Assessing the commutability of reference material formats for the harmonization of amyloid beta measurements. Clin Chem Lab Med 54 (2016), 1177–1191.
31. Pannee, J., Portelius, E., Minthon, L., Gobom, J., Andreasson, U., Zetterberg, H., et al. Reference measurement procedure for CSF amyloid beta (Aβ)1–42 and the CSF Aβ1-42/Aβ1-40 ratio—a cross-validation study against amyloid PET. J Neurochem 139 (2016), 651–658.
32. Janelidze, S., Zetterberg, H., Mattsson, N., Palmqvist, S., Vanderstichele, H., Lindberg, O., et al. CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol 3 (2016), 154–165.
33. Chiasserini, D., Biscetti, L., Farotti, L., Eusebi, P., Salvadori, N., Lisetti, V., et al. Performance evaluation of an automated ELISA system for Alzheimer's disease detection in clinical routine. J Alzheimers Dis 54 (2016), 55–67.
34. Lelental, N., Brandner, S., Kofanova, O., Blennow, K., Zetterberg, H., Andreasson, U., et al. Comparison of different matrices as potential quality control samples for neurochemical dementia diagnostics. J Alzheimers Dis 52 (2016), 51–64.
35. Janssen, L., Sobott, F., De Deyn, P., Van Dam, D., Chem, C., Signal loss due to epitope masking and steric hindrance in ELISA analysis of amyloid-beta can be recovered by a novel sample pre-treatment method. MethodsX 2 (2014), 112–123.
36. Fronek, K., Lange, P., Spreer, A., Eiffert, H., Nau, R., Bacterial contamination and the transport vial material affect cerebrospinal fluid concentrations of β-amyloid and tau protein as determined by enzyme immunoassay. Dement Geriatr Cogn Disord 32 (2011), 126–134.
37. Berge, G., Lauridsen, C., Sando, S.B., Holder, D., Møller, I., Aasly, J.O., et al. Effect of Tween-20 on core biomarkers measured in cerebrospinal fluid from patients with Alzheimer's disease, mild cognitive impairment, or healthy control individuals. J Alzheimers Dis 49 (2015), 493–502.
38. Kuhlmann, J., Andreasson, U., Pannee, J., Bjerke, M., Portelius, E., Leinenbach, A., et al. CSF Aβ1–42—an excellent but complicated Alzheimer's biomarker—a route to standardisation. Clin Chim Acta, 2016 http://dx.doi.org/10.1016/j.cca.2016.05.014 [E-pub ahead of print].